Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.
